fda warning letters glp-1 september 2025 Prescription Drug Freight Fraud Report, September 2025 – Partnership for Safe Medicines

FDA Warning Letter Breakdown: Sterility Failures, Subpotent GLP-1 Drugs, and a Compounding Pharmacy Operating Without Control

27.65

★★★★☆4.8 (126)

Thinking about buying GLP-1 and other products labeled “for research purposes” or “not for human consumption”? Think again. These products have not been reviewed by FDA for safety, effectiveness or

26.65

★★★★★4.9 (98)

Thinking about buying GLP-1 and other products labeled “for research purposes” or “not for human consumption”? Think again. These products have not been reviewed by FDA for safety, effectiveness or quality and

24.23

★★★★★5.0 (157)

September 15, 2025: Telehealth company must stop implying its compounded GLP -1 is FDA-approved, warns FDA – Partnership for Safe Medicines

23.17

★★★★★4.7 (84)

FDA Drug Recalls and Warnings: Illegal GLP-1 Sales and Misleading Marketing by Novo Nordisk and Eli Lilly

21.03

★★★★★4.9 (203)

FDA Issues 30 Warning Letters to Telehealth Firms Over Misleading Compounded GLP-1 Marketing

24.42

★★★★★5.0 (176)

FDA Targets GLP-1 and Peptide Compounding, Advertising and 'Research Use Only' Labeling

21.16

★★★★★4.8 (132)